Please assess the completion status of the following clinical trial:

Trial Title: Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients \>45 or \>40 years with known atherosclerotic events (examples include MI, Stroke) and able to provide informed consent (females must be either post-menopausal for one year, surgically sterile, or using effective contraception. Oral contraceptives are disallowed.~2. Patients with Type II Diabetes with HbA1c ≤ 9.0 on stable anti-glycemic regimen that may include oral and/or injectable therapy (GLP-1/Insulin etc.). Changes in dose of glycemic regimen is allowed during the course of the trial if felt to be clinically appropriate.~3. GFR \<90 and evidence of proteinuria (Urine albumin/creatinine ratio of \>30 mg/g or equivalent) in a urine specimen within 12 months OR GFR \<60 mg/g regardless of proteinuria.~4. Patients must be on ACE and/or ARB therapy with no planned dose adjustments.~Exclusion Criteria:~1. Uncontrolled hypertension (SBP\>160 and/or DBP\>95 mmHg at visit 0 (screening) and SBP \>145 mm Hg at visit 2).~2. GFR (MDRD) of \<15 at Visit 0 (screening).~3. Hyperkalemia defined as serum K+≥ 5.1 meq/L at visit 0 (screening).~4. LDL cholesterol \>150 mg/dl.~5. Plasma triglycerides \>400 mg/dl.~6. Contraindications to MRI (metallic implants, severe claustrophobia).~7. Acute coronary syndrome, Transient ischemic attack, CVA or critical limb ischemia during the last 6 months or coronary/peripheral revascularization within the last 3 months.~8. Evidence of a secondary form of hypertension.~9. Initiation of new therapy with statins, ACEI/ARB, anti-oxidants, CCBs, diuretics, β blockers.~10. Type I diabetes mellitus~11. Known contraindication, including history of allergy to Spironolactone.~12. . Any surgical or medical condition which might alter pharmacokinetics of drug (e.g. renal transplant, liver failure, liver transplant).~13. Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.~14. Significant hyponatremia defined as Na \<130 meq/L.~15. History of prior malignancy including leukemia and lymphoma (but not basal cell skin cancer, cured squamous cell cancer and localized Prostate cancer).~16. History of any severe, life-threatening disease.~17. Any surgical or medical conditions which places the patient at higher risk derived from his/her participation into the study, or likely to prevent patient from complying with requirements.~18. History of drug abuse within the last 2 years, noncompliance and unwillingness/inability to consent.~19. Pregnant women and nursing mothers.~20. Class III or IV Congestive Heart Failure.~21. Primary Hyperaldosteronism.

- Gender: ALL
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spironolactone (Type: EXPERIMENTAL): Spironolactone
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete